The pretreament of the ccRCC cells with proteasome inhibitors, however, abolished the stability differences of the activated EGFR between the 786-VHL and 786-mock cells: the activated EGFR was not degraded during the experiment (Fig. 3B, 3C, 3H, 3I, 3J, and 3K). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.